Medchemexpress LLC ABT-639 | 1235560-28-7 | 99.3% | 455.91 | 5 MG

Supplier:  Medchemexpress LLC HY197215MG

ABT-639 is a novel, peripherally acting, selective T-type Ca2+ channel blocker. It is for research use only and not sold to patients.

• Novel, peripherally acting, selective T-type Ca2+ channel blocker.
• Blocks recombinant human T-type (Cav3.2) Ca2+ channels (IC50=2 μM).
• Attenuates low voltage-activated (LVA) currents in rat DRG neurons (IC50=8 μM).
• Less active at other Ca2+ channels (e.g., Cav1.2, Cav2.2) (IC50>30 mM).
• High oral bioavailability (%F=73), low protein binding (88.9%), low brain:plasma ratio (0.05:1) in rodents.
• Produces dose-dependent antinociception in rat model of knee joint pain (ED50=2 mg/kg, p.o.).
• Increases tactile allodynia thresholds in multiple models of neuropathic pain (10-100 mg/kg, p.o.).
• Does not attenuate hyperalgesia in inflammatory pain models.
• Does not significantly alter hemodynamic or psychomotor function at higher doses (e.g., 100-300 mg/kg).

Catalog No. 50-004-00971